El Salvador vs Peru: Average cost of multi drug-resistant tuberculosis treatment
El Salvador
574 constant 2022 US$
in 2024
Peru
570 constant 2022 US$
in 2024
El Salvador rank
73rd
Peru rank
75th
Average cost of multi drug-resistant tuberculosis treatment over time
- El Salvador
- Peru
How they compare
El Salvador currently reports 574 constant 2022 US$ against 570 constant 2022 US$ in Peru, a difference of 4 constant 2022 US$.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Peru ahead.
El Salvador ranks 73rd and Peru ranks 75th of 92 countries.
El Salvador has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | El Salvador | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,590 constant 2022 US$ | 1,408 constant 2022 US$ | 182.33 constant 2022 US$ | El Salvador |
| 2020s | 3,208 constant 2022 US$ | 1,327 constant 2022 US$ | 1,881 constant 2022 US$ | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, El Salvador or Peru?
- El Salvador, at 574 constant 2022 US$ against 570 constant 2022 US$ in Peru as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between El Salvador and Peru?
- 4 constant 2022 US$, with El Salvador ahead.
- How many years of comparable data are there for El Salvador and Peru?
- 8 years are reported by both, from 2017 to 2024.
- How do El Salvador and Peru rank globally for average cost of multi drug-resistant tuberculosis treatment?
- El Salvador ranks 73rd and Peru ranks 75th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.